Posted by Michael Wonder on 27 Dec 2021
Celularity receives fast track designation from U.S. FDA for its NK cell therapy CYNK-001 in development for the treatment of AML
27 December 2021 - Celularity today announced the U.S. FDA has granted fast track designation for its non-genetically modified cryopreserved human placental haematopoietic stem cell-derived natural killer cell therapy, CYNK-001, in development for the treatment of acute myeloid leukaemia.
CYNK-001 is a cryopreserved allogeneic off the shelf cell therapy enriched for CD56+/CD3- natural killer cells expanded from human placental CD34 positive cells.
